Post-transplant BRAF/MEK inhibitor maintenance sustains complete remission in BRAF V600E-mutant histiocytic sarcoma.
Ihab Karim, Tobias Arnold, Andreas Bräuninger et al.
✦ AI-curated · Sources linked
Case in brief
A patient with refractory BRAF V600E-mutant histiocytic sarcoma achieved complete remission with BRAF/MEK inhibition and then underwent allogeneic stem cell transplantation. Dabrafenib and trametinib maintenance began early after engraftment. During follow-up exceeding one year, the patient remained in complete remission, with no radiological or molecular evidence of disease; circulating tumor DNA testing remained negative for mutations detected previously.
What made this case unusual
The report describes sustained remission after an integrated sequence of targeted therapy, allogeneic transplantation, and post-transplant dabrafenib–trametinib maintenance in refractory BRAF V600E-mutant histiocytic sarcoma.
Diagnostic / clinical pearl
In this case, circulating tumor DNA remained negative for previously detected mutations alongside radiological and clinical remission, providing a molecular measure of disease status during follow-up.
Why it matters
The case supports further evaluation of post-transplant targeted maintenance as part of an integrated approach to high-risk BRAF-mutant histiocytic sarcoma.